Pfizer’s sasanlimab combo significantly improves event-free survival in BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Tuesday, April 29, 2025, 14:00 Hrs [IS ...

NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Pfizer recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company ...

As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in the Philippines, coinciding with its 175th-year global milestone.

Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price rose 1.5% during mid-day trading on Thursday following a dividend announcement from the company. The stock traded as high as $22.74 and ...

Pharmaceutical companies have stepped up pressure on the Government to push back against proposed new regulations of the sector, which pharma giant Pfizer privately warned could damage the Irish ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13 ...

Pfizer is ending the development of its GLP-1 weight loss drug, danuglipron. A patient in a clinical trial experienced a liver injury, potentially due to the drug. Pfizer has a massive pipeline ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO ...